Biotech | April 12, 2022
Cambrex completes large-scale US API expansion
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Subscribe To Our Newsletter & Stay Updated
